{"id":937867,"date":"2026-02-18T08:35:28","date_gmt":"2026-02-18T13:35:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/"},"modified":"2026-02-18T08:35:28","modified_gmt":"2026-02-18T13:35:28","slug":"alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/","title":{"rendered":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens"},"content":{"rendered":"

<\/p>\n

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL<\/b>\u00ae Dosing Regimens<\/b><\/p>\n

VANCOUVER, British Columbia & GRAPEVINE, Texas–(BUSINESS WIRE<\/a>)–
\nAlpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition,\u201d \u201cACI,\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled \u201cDosage Regimens for Benzgalantamine.\u201d<\/i><\/p>\n

\nThe issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer\u2019s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company\u2019s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition\u2019s FDA-approved therapy for mild to moderate Alzheimer\u2019s disease.<\/p>\n

\n\u201cThis newly issued patent meaningfully strengthens the intellectual property protection surrounding ZUNVEYL by covering clinically relevant dosing regimens for oral administration,\u201d said Michael McFadden, Chief Executive Officer of Alpha Cognition. \u201cThese method-of-use claims extend and reinforce our existing patent portfolio, supporting ZUNVEYL\u2019s long-term differentiation and enhancing its commercial value in the U.S. market.\u201d<\/p>\n

\nThe issuance of this patent further advances Alpha Cognition\u2019s long-term intellectual property strategy by protecting key methods of administering benzgalantamine and extending exclusivity beyond existing patent coverage. The Company believes this patent underscores the innovative nature of its benzgalantamine research and supports durable market protection for ZUNVEYL.<\/p>\n

\nAbout Alpha Cognition Inc.<\/p>\n

\nAlpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer\u2019s disease and Cognitive Impairment with mild Traumatic Brain Injury (\u201cmTBI\u201d), for which there are currently no approved treatment options.<\/p>\n

\nZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, with expected minimal gastrointestinal side effects. ZUNVEYL\u2019s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer\u2019s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.<\/p>\n

This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward\u2010looking statement that reflects the Company\u2019s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2010looking statements by the words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2010looking statements may include statements regarding the Company\u2019s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL\u2019s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company\u2019s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company\u2019s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company\u2019s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company\u2019s filings with Canadian securities regulatory authorities and available at <\/i>www.sedar.com<\/i><\/a> and the Company\u2019s filings with the United States Securities and Exchange Commission (the \u201cSEC\u201d), including those risk factors under the heading \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K as filed with the SEC on March 31, 2025 and available at <\/i>www.sec.gov<\/i><\/a>. These forward\u2010looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward\u2010looking statements for any reason, even if new information becomes available in the future, except as required by law.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260218956050\/en\/<\/a><\/span><\/p>\n

Investor Relations
\n<\/b>
LifeSci Advisors, PJ Kelleher
\n
pkelleher@lifesciadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> Texas United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Neurology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens VANCOUVER, British Columbia & GRAPEVINE, Texas–(BUSINESS WIRE)– Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition,\u201d \u201cACI,\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled \u201cDosage Regimens for Benzgalantamine.\u201d The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer\u2019s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company\u2019s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition\u2019s FDA-approved therapy for mild … <\/p>\n

Continue reading “Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937867","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens VANCOUVER, British Columbia & GRAPEVINE, Texas–(BUSINESS WIRE)– Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition,\u201d \u201cACI,\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled \u201cDosage Regimens for Benzgalantamine.\u201d The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer\u2019s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company\u2019s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition\u2019s FDA-approved therapy for mild … Continue reading "Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T13:35:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens\",\"datePublished\":\"2026-02-18T13:35:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/\"},\"wordCount\":880,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/\",\"name\":\"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-02-18T13:35:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/","og_locale":"en_US","og_type":"article","og_title":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens - Market Newsdesk","og_description":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens VANCOUVER, British Columbia & GRAPEVINE, Texas–(BUSINESS WIRE)– Alpha Cognition Inc. (NASDAQ: ACOG) (\u201cAlpha Cognition,\u201d \u201cACI,\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled \u201cDosage Regimens for Benzgalantamine.\u201d The issued patent includes claims covering methods of orally administering benzgalantamine for the treatment of mild to moderate Alzheimer\u2019s disease using specific dosing regimens. The patent is expected to provide U.S. patent protection through July 2045 and represents an important addition to the Company\u2019s intellectual property portfolio supporting ZUNVEYL, Alpha Cognition\u2019s FDA-approved therapy for mild … Continue reading \"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-18T13:35:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens","datePublished":"2026-02-18T13:35:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/"},"wordCount":880,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/","name":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-02-18T13:35:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260218956050r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpha-cognition-announces-issuance-of-additional-u-s-patent-covering-zunveyl-dosing-regimens\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL\u00ae Dosing Regimens"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937867"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937867\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}